Verastem Company Profile (NASDAQ:VSTM)

About Verastem

Verastem logoVerastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company's VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company's VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: VSTM
  • CUSIP: 92337C10
Key Metrics:
  • Previous Close: $1.36
  • 50 Day Moving Average: $1.35
  • 200 Day Moving Average: $1.41
  • 52-Week Range: $1.05 - $2.43
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.27
  • P/E Growth: -0.84
  • Market Cap: $48.83M
  • Outstanding Shares: 36,992,000
Additional Links:
Companies Related to Verastem:

Analyst Ratings

Consensus Ratings for Verastem (NASDAQ:VSTM) (?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $3.17 (139.90% upside)

Analysts' Ratings History for Verastem (NASDAQ:VSTM)
DateFirmActionRatingPrice TargetDetails
8/9/2016Cantor FitzgeraldReiterated RatingBuy$3.00View Rating Details
8/5/2016Jefferies GroupReiterated RatingHold$1.50View Rating Details
3/7/2016HC WainwrightReiterated RatingBuy$5.00View Rating Details
11/11/2015Oppenheimer Holdings Inc.Reiterated RatingMarket PerformView Rating Details
9/29/2015JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
9/29/2015Raymond James Financial Inc.DowngradeStrong-Buy -> Outperform$12.00 -> $3.00View Rating Details
9/28/2015MizuhoDowngradeBuy -> Neutral$21.00 -> $2.00View Rating Details
9/28/2015Roth CapitalDowngradeBuy -> Neutral$23.00 -> $2.00View Rating Details
12/16/2014Wells Fargo & Co.Initiated CoverageOutperformView Rating Details
(Data available from 9/30/2014 forward)


Earnings History for Verastem (NASDAQ:VSTM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016Q2($0.29)($0.23)ViewN/AView Earnings Details
5/9/2016($0.30)($0.22)ViewN/AView Earnings Details
3/3/2016Q415($0.36)($0.32)ViewListenView Earnings Details
8/10/2015Q2($0.45)($0.42)ViewN/AView Earnings Details
5/11/2015Q1($0.41)($0.46)ViewN/AView Earnings Details
3/10/2015($0.54)($0.53)ViewN/AView Earnings Details
10/30/2014($0.51)($0.52)ViewN/AView Earnings Details
5/8/2014($0.43)($0.51)ViewN/AView Earnings Details
3/6/2014Q4($0.47)($0.45)ViewListenView Earnings Details
11/12/2013Q3($0.44)($0.47)ViewN/AView Earnings Details
8/13/2013Q2 2013($0.41)($0.49)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.43)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Verastem (NASDAQ:VSTM)
Current Year EPS Consensus Estimate: $-0.94 EPS
Next Year EPS Consensus Estimate: $-1.04 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.32)($0.32)($0.32)
Q2 20161($0.33)($0.33)($0.33)
Q3 20162($0.26)($0.24)($0.25)
Q4 20162($0.28)($0.25)($0.27)
(Data provided by Zacks Investment Research)


Dividend History for Verastem (NASDAQ:VSTM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Verastem (NASDAQ:VSTM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/29/2015Monica SinghGeneral CounselBuy1,000$6.95$6,950.00View SEC Filing  
6/29/2015Robert ForresterCEOBuy2,000$7.11$14,220.00View SEC Filing  
6/18/2015Dan PatersonCOOBuy1,000$8.05$8,050.00View SEC Filing  
6/17/2015Robert ForresterCEOBuy1,000$7.97$7,970.00View SEC Filing  
1/28/2015Christoph H WestphalChairmanBuy1,230,769$6.50$7,999,998.50View SEC Filing  
1/28/2015Timothy J BarberichDirectorBuy38,462$6.50$250,003.00View SEC Filing  
12/29/2014Joanna HorobinInsiderBuy750$8.60$6,450.00View SEC Filing  
12/29/2014S. Louise PhanstielDirectorBuy10,000$8.54$85,400.00View SEC Filing  
12/26/2014Stephen A SherwinDirectorBuy2,500$8.56$21,400.00View SEC Filing  
12/24/2014Paul A FriedmanDirectorBuy3,000$8.31$24,930.00View SEC Filing  
12/23/2014Henri A TermeerDirectorBuy19,100$8.09$154,519.00View SEC Filing  
12/23/2014Monica SinghGeneral CounselBuy1,000$8.09$8,090.00View SEC Filing  
12/19/2014Christoph H WestphalChairmanBuy1,500$8.50$12,750.00View SEC Filing  
12/19/2014Dan PatersonCOOBuy2,000$8.52$17,040.00View SEC Filing  
12/19/2014Robert ForresterCEOBuy1,000$8.66$8,660.00View SEC Filing  
11/11/2014Alison Frances LawtonDirectorBuy2,500$9.17$22,925.00View SEC Filing  
9/17/2014Michael KauffmanDirectorBuy3,000$9.10$27,300.00View SEC Filing  
5/30/2014Timothy J BarberichDirectorBuy1,000$9.90$9,900.00View SEC Filing  
5/20/2014Richard AldrichDirectorBuy1,000$8.37$8,370.00View SEC Filing  
5/15/2014Dan PatersonInsiderBuy1,000$7.47$7,470.00View SEC Filing  
5/14/2014Christoph WestphalChairmanBuy2,000$7.56$15,120.00View SEC Filing  
5/13/2014Robert ForresterCEOBuy1,000$7.62$7,620.00View SEC Filing  
11/18/2013Christoph WestphalDirectorBuy1,000$9.60$9,600.00View SEC Filing  
11/11/2013Richard AldrichDirectorBuy1,000$10.93$10,930.00View SEC Filing  
11/4/2013Richard AldrichDirectorBuy1,000$10.51$10,510.00View SEC Filing  
10/28/2013Richard AldrichDirectorBuy1,000$11.26$11,260.00View SEC Filing  
10/21/2013Richard AldrichDirectorBuy1,000$12.57$12,570.00View SEC Filing  
10/14/2013Richard AldrichDirectorBuy1,000$10.56$10,560.00View SEC Filing  
10/7/2013Richard AldrichDirectorBuy1,000$11.53$11,530.00View SEC Filing  
9/30/2013Richard AldrichDirectorBuy1,000$12.55$12,550.00View SEC Filing  
9/23/2013Richard AldrichDirectorBuy1,000$13.17$13,170.00View SEC Filing  
9/16/2013Richard AldrichDirectorBuy1,000$13.81$13,810.00View SEC Filing  
9/9/2013Richard AldrichDirectorBuy1,000$14.04$14,040.00View SEC Filing  
9/3/2013Richard AldrichDirectorBuy1,000$14.07$14,070.00View SEC Filing  
8/26/2013Richard AldrichDirectorBuy1,000$14.21$14,210.00View SEC Filing  
8/19/2013Richard AldrichDirectorBuy1,000$13.45$13,450.00View SEC Filing  
8/12/2013Richard AldrichDirectorBuy1,000$14.75$14,750.00View SEC Filing  
8/5/2013Richard AldrichDirectorBuy1,000$15.25$15,250.00View SEC Filing  
7/29/2013Richard AldrichDirectorBuy1,000$15.15$15,150.00View SEC Filing  
7/24/2013Richard AldrichDirectorBuy1,000$16.39$16,390.00View SEC Filing  
7/15/2013Richard AldrichDirectorBuy1,000$17.19$17,190.00View SEC Filing  
7/8/2013Richard AldrichDirectorBuy1,000$14.69$14,690.00View SEC Filing  
7/1/2013Richard AldrichDirectorBuy1,000$14.11$14,110.00View SEC Filing  
6/13/2013Robert ForresterCOOBuy1,000$11.39$11,390.00View SEC Filing  
6/12/2013Henri A TermeerDirectorBuy5,823$9.74$56,716.02View SEC Filing  
6/12/2013Lp Chp IIIMajor ShareholderBuy48,171$9.40$452,807.40View SEC Filing  
6/11/2013S. Louise PhanstielDirectorBuy12,000$9.30$111,600.00View SEC Filing  
6/7/2013Christoph H WestphalCEOBuy1,000$9.06$9,060.00View SEC Filing  
5/13/2013John K ClarkeDirectorBuy25,000$9.74$243,500.00View SEC Filing  
5/1/2013John K ClarkeDirectorBuy10,000$9.66$96,600.00View SEC Filing  
4/17/2013John K ClarkeDirectorBuy5,631$9.50$53,494.50View SEC Filing  
12/18/2012Lp Chp IIIMajor ShareholderBuy6,193$7.87$48,738.91View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Verastem (NASDAQ:VSTM)
DateHeadline logoCancer Research UK, MSD and Verastem Collaborate to Trial New Combination of Immunotherapy Drugs - Business Wire (press release) (NASDAQ:VSTM) - September 30 at 7:17 AM logoCancer Research UK, MSD and Verastem Collaborate to Trial New Combination of Immunotherapy Drugs (NASDAQ:VSTM) - September 30 at 7:17 AM
News IconLatest Analyst Ratings For Verastem, Inc. (VSTM) - The De Soto Edge (NASDAQ:VSTM) - September 29 at 7:54 PM
News IconInterested Penny Stock Investors Keen on Shares of Verastem, Inc. (NASDAQ:VSTM) - Duncan Research (NASDAQ:VSTM) - September 28 at 7:47 PM
News IconPenny Stock Investors are Growing Curious About Verastem, Inc. (NASDAQ:VSTM) - Duncan Research (NASDAQ:VSTM) - September 27 at 7:56 PM logoHot Stocks: Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP), Verastem, Inc. (NASDAQ:VSTM), Aaron's, Inc. (NYSE:AAN ... - KC Register (NASDAQ:VSTM) - September 26 at 8:03 PM
News IconUnder the Microscope: Zeroing in on Shares of Verastem, Inc. (NASDAQ:VSTM) - Duncan Research (NASDAQ:VSTM) - September 26 at 8:03 PM
News IconStock Update on Earnings & Estimates for Verastem, Inc. (NASDAQ:VSTM) - Frisco Fastball (NASDAQ:VSTM) - September 26 at 8:13 AM
News IconKeen Investors Find News on Verastem, Inc. (NASDAQ:VSTM) - Duncan Research (NASDAQ:VSTM) - September 24 at 6:56 AM
News IconPenny Stock Investors Keen on Shares of Verastem, Inc. (NASDAQ:VSTM) - Duncan Research (NASDAQ:VSTM) - September 22 at 7:39 PM
News IconUnder the Microscope, Zeroing in at Verastem, Inc. (NASDAQ:VSTM) - Duncan Research (NASDAQ:VSTM) - September 22 at 7:39 PM
News IconStock Perspective: Verastem, Inc. (NASDAQ:VSTM) Earnings in View - Frisco Fastball (NASDAQ:VSTM) - September 21 at 7:31 PM
News IconPenny Stock Investors Take an Interest in Verastem, Inc. (NASDAQ:VSTM) - Duncan Research (NASDAQ:VSTM) - September 21 at 7:31 PM
News IconUnder the Microscope: Getting a Closer Look at Shares of Verastem, Inc. (NASDAQ:VSTM) - Duncan Research (NASDAQ:VSTM) - September 19 at 7:55 PM
News IconAnalysts Place Verastem, Inc. (NASDAQ:VSTM) Under the Lens of the Microscope - Post News (NASDAQ:VSTM) - September 15 at 8:08 PM logoInvestors Are Watching: Symantec Corporation (NASDAQ:SYMC), Verastem, Inc. (NASDAQ:VSTM), Cypress ... - KC Register (NASDAQ:VSTM) - September 15 at 11:47 AM
News IconKeen Investors Narrowing Their Focus on Verastem, Inc. (NASDAQ:VSTM) - Duncan Research (NASDAQ:VSTM) - September 14 at 8:14 PM
News IconPenny Stock Investors Highly Curious in Shares of Verastem, Inc. (NASDAQ:VSTM) - Duncan Research (NASDAQ:VSTM) - September 14 at 12:23 PM
News IconPlacing Verastem, Inc. (NASDAQ:VSTM) Shares Under the Microscope - Post News (NASDAQ:VSTM) - September 8 at 11:58 AM logoVerastem to Present at Rodman & Renshaw 18th Annual Global Investment Conference (NASDAQ:VSTM) - September 6 at 8:06 PM
News IconStock in Review: Taking a Closer Look at Verastem, Inc. (NASDAQ:VSTM) Shares - Post News (NASDAQ:VSTM) - September 1 at 11:22 AM logoVERASTEM, INC. Financials (NASDAQ:VSTM) - August 13 at 7:41 PM logoVERASTEM, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:VSTM) - August 9 at 11:39 AM logoVerastem reports 2Q loss (NASDAQ:VSTM) - August 8 at 8:23 PM logoVerastem Reports Second Quarter 2016 Financial Results (NASDAQ:VSTM) - August 8 at 8:23 PM logoVerastem Inc.: Verastem Reports Second Quarter 2016 Financial Results (NASDAQ:VSTM) - August 8 at 8:23 PM logoBRIEF-Verastem reports Q2 loss per share $0.23 (NASDAQ:VSTM) - August 8 at 9:24 AM logoVerastem Inc. (VSTM) Jumps 13.85% on July 28 - (NASDAQ:VSTM) - July 30 at 7:20 PM
News IconVerastem Inc (NASDAQ:VSTM): Don’t Believe The Hype (NASDAQ:VSTM) - July 30 at 10:52 AM logoTake a look at Analysts Tips: Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) , Verastem, Inc. (NASDAQ:VSTM) - Street Updates (NASDAQ:VSTM) - July 29 at 8:28 PM
News IconPerformance Overview of the company: Verastem, Inc. (NASDAQ:VSTM) - News Oracle (NASDAQ:VSTM) - July 29 at 8:28 PM logoThe Insider Activity Don't Lie: Verastem, Inc. (NASDAQ:VSTM) - Review Fortune (NASDAQ:VSTM) - July 29 at 8:28 PM
News IconVerastem Incorporated (NASDAQ:VSTM) Sellers Covered 9.33% of Their Shorts - Consumer Eagle (NASDAQ:VSTM) - July 20 at 9:16 PM
News IconVerastem, Inc. (NASDAQ:VSTM): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:VSTM) - July 19 at 8:21 PM
News IconTrading Performance and Target Watch for Verastem, Inc. (NASDAQ:VSTM) - Press Telegraph (NASDAQ:VSTM) - July 18 at 7:10 AM
News IconShares Moving Down on the Week: Verastem, Inc. (NASDAQ:VSTM) - Engelwood Daily (NASDAQ:VSTM) - July 17 at 7:16 AM
News IconWere Analysts Bearish Verastem Inc (NASDAQ:VSTM) This Week? - Press Telegraph (NASDAQ:VSTM) - July 16 at 11:21 AM logoVerastem : to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference (NASDAQ:VSTM) - July 15 at 1:31 PM logoHowland Capital Management Lowers stake in Verastem Inc (VSTM) - Trade Calls (NASDAQ:VSTM) - July 13 at 11:01 AM
News IconVerastem Inc Institutional Investor Sentiment Worsened in Q1 2016 - Consumer Eagle (NASDAQ:VSTM) - July 12 at 8:25 PM
News IconVerastem, Inc. (NASDAQ:VSTM) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:VSTM) - July 12 at 8:25 PM
News IconWere Analysts Bullish Verastem Inc (NASDAQ:VSTM) This Week? - Engelwood Daily (NASDAQ:VSTM) - July 10 at 7:01 AM
News IconVerastem Incorporated (NASDAQ:VSTM) Sellers Covered 9.33% of Their Shorts - Engelwood Daily (NASDAQ:VSTM) - July 8 at 10:59 AM logoVerastem, Inc. (VSTM) Updated Price Targets - FTSE News (NASDAQ:VSTM) - July 8 at 10:59 AM logoVerastem to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference (NASDAQ:VSTM) - July 7 at 10:52 AM
News IconCutting Edge Stocks in Focus - Amedica Corporation (NASDAQ:AMDA), Verastem (NASDAQ:VSTM), HCI Group (NYSE ... - Seneca Globe (NASDAQ:VSTM) - July 6 at 8:41 PM logoVerastem to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference (NASDAQ:VSTM) - July 6 at 7:00 AM logoStudy Published in Nature Medicine Highlights Potential Role of FAK Inhibition in Pancreatic Cancer (NASDAQ:VSTM) - July 5 at 8:31 AM logoVerastem, Inc. (VSTM) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:VSTM) - July 5 at 6:58 AM
News IconVerastem Incorporated (NASDAQ:VSTM) Shorts Decreased by 9.33% After Short Covering - Press Telegraph (NASDAQ:VSTM) - July 3 at 6:49 AM


Verastem (NASDAQ:VSTM) Chart for Friday, September, 30, 2016

Last Updated on 9/30/2016 by Staff